Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (January 2021)
33 slides from Cocrystal Pharma's investor presentation, Jan 11, 2021
Slide 1: Investor Presentation January 2021
NASDAQ: COCP cocrystalpharma.com CO CRYSTAL Investor Presentation PHARMA,INC. January 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. ("Merck"), including the anticipated charac
Slide 3: About Cocrystal Pharma
181 About Cocrystal Pharma Overview Target Diseases Clinical-Stage Antiviral Company Influenza Proprietary Drug Discovery Platiorm COVID-19 Merck Collaboration Hepatitis C Potential For Prophylactic and Therapeutic Drugs Norovirus Gastroenteritis
Slide 4: Investment Highlights
18 Investment Highlights e Applying proprietary structure-based drug design technology to develop first- and best- in-class broad-spectrum antiviral drugs e Large market opportunities for the treatment of acute and chronic viral diseases including seasonal and pandemic influenza, COVID-19, hepatitis
Slide 5: Management Team
Management Team Gary Wilcox, Ph.D. Chairman and Chief Executive Officer + 35+ years of executive biotech leadership experience; played key role in Cialis development Sam Lee, Ph.D. President + 25+ years of anti-infective drug discovery research experience; played key role in early development of pho
Slide 6: Proprietary Technology and Drug Discovery Platform
Ake Lot Proprietary Technology and Drug Discovery Platform Technology Platform Based on Nobel Prize-winning technology + Near-atomic resolution + X-ray quality crystal production + Drug pocket selection + Hit-to-lead process + Lead optimization + Drug candidates Drug Discovery Platform Crystal Produ
Slide 7: Robust Development Pipeline in High-Value Indications
Ake Lot Robust Development Pipeline in High-Value Indications Program Discovery Preclinical Phase1 Phase 2a Influenza A/B Influenza A/B inhibitor ollaboration with & Replication and COvID-19 Protease Inhibitor Pandemic CC-42344 InfluenzaA (Influenza A PB2 Inhibitor) Hepatitis C CC-31244 (HCV) (Pan-g
Slide 8: Overview | Antiviral Program: Influenza A/B Merck Collaboration
Overview | Antiviral Program: Influenza A/B Merck Collaboration
Slide 9: Influenza A/B Merck Collaboration
Influenza A/B Merck Collaboration > MERCK 4 N Influenza A/B Crystals ¢ Broad-spectrum, potent dual influenza A/B drug candidates * Binds to highly conserved site of influenza A and B replication complex ° Expected to be active against seasonal, pandemic and existing drug- resistant influenza A and B
Slide 10: Collaboration Terms Overview
Lot Collaboration Terms Overview Eligible to receive up to $156 million in milestone payments + royalties on product sales « Exclusive worldwide license and collaboration agreement to discover and develop proprietary influenza A/B antiviral agents signed in January 2019 « Agreement structure during
Slide 11: Overview | Antiviral Program: COVID-19
11 Overview | Antiviral Program: COVID-19
Slide 12: Kansas State University Research Foundation Agreements
Ake Lot Kansas State University Research Foundation Agreements Cocrystal acquired exclusive patent rights and know-how for coronavirus and norovirus therapeutics for human use « License agreements with KSURF in 2020 to further develop proprietary broad-spectrum compounds for coronavirus and noroviru
Slide 13: Status of COVID-19 Treatment
Status of COVID-19 Treatment 4 N Cocrystal is researching and developing multiple options needed to prevent or treat COVID-19 There is no approved COVID-19 antiviral prophylactic treatment There is no effective COVID-19 antiviral therapeutic treatment 13 C@CRYSTAL
Slide 14: Stages of COVID-19
aS 1@t Stages of COVID-19 xT Stage | Stage Il Stage III (Early Infection) (Pulmonary Phase) (Hyperinflammation Phase) HA i IIB Viral response phase Severity of Illness Host inflammatory response phase Fa Time course Mild constitutional symptoms Shortness of breath without ARDS Clinical Symptoms Feve
Slide 15: COVID-19 Program Status
Ake ~F COVID-19 Program Status * Potential to be effective treatment for COVID-19 Develop SARS-CoV-2 inhibitors using proprietary platform technology Targeting viral replication complex and protease Potential first-in-class therapeutic and prophylactic treatment Achieved Milestones and Next Steps: ¥
Slide 16: Overview | Antiviral Program: Pandemic Influenza A
16 Overview | Antiviral Program: Pandemic Influenza A
Slide 17: Significant Need for Pandemic Influenza Therapies
Ake Lot Significant Need for Pandemic Influenza Therapies Seasonal and pandemic infections 1 Billion 3-5 Million Up to 650,000 cases annually? cases of severe deaths worldwide illness annually! annually’ Current antiviral treatments are burdened by significant viral resistance Approved influenza the
Slide 18: Influenza Remains a Major U.S. and Global Concern
A, NS ~ oe Influenza Remains a Major U.S. and Global Concern Flu season deaths top 80,000 last year, CDC says September27, 2018 US on track for one of TV. the worst flu seasons in decades Jan, 6, 2020 Science fi Swine flu strain with human pandemic potential increasingly found in pigs in China jun 2
Slide 19: CC-42344: Influenza A Pandemic Antiviral Drug
rot CC-42344: Influenza A Pandemic Antiviral Drug Influenza A Crystals ~F Binds to the highly conserved pocket on replication enzyme Exhibits broad spectrum activity against seasonal and pandemic influenza strains Favorable preclinical safety profile and pharmacokinetic properties Multiple routes of
Slide 20: CC-42344 Shows Strong Synergistic Effects with Approved Influenza Antivirals
rot CC-42344 Shows Strong Synergistic Effects with ww Approved Influenza Antivirals Polymerase Inhibitor Favipiravir = /n vitro combination studies with Xofluza, Tamiflu, NY and Favipiravir demonstrated strong synergistic effects os = CC-42344 shows high barrier to drug resistance and active against
Slide 21: CC-42344: Pharmacological, Safety, Toxicity and PK Evaluations Successfully Completed
rot CC-42344: Pharmacological, Safety, Toxicity and nF PK Evaluations Successfully Completed In vitro antiviral profiling against seasonal and pandemic influenza A strains Cytotoxicity including larger screen: HepG2/high content analysis and 13 cell lines Caco-2 bidirectional permeability CYP inhibi
Slide 22: Overview | Antiviral Program: Hepatitis C
22 Overview | Antiviral Program: Hepatitis C
Slide 23: Hepatitis C Strategy
cA Lol Hepatitis C Strategy Lead program CC-31244, Phase 2a study completed for the treatment of HCV CurrentHCV Market Overview Evolution of Shorter Therapy * Ultrashort treatment strategy Nucleoside/NS5A Inhibitors Protease/NSSA Inhibitors * Limitations of existing long-term HCV therapies: * Longer
Slide 24: CC-31244: HCV Non-Nucleoside Inhibitor (NNI)
~ ie CC-31244: HCV Non-Nucleoside Inhibitor (NNI) HCV GT1-—GT6 NS5B Polymerase Crystals Next Generation Combination (Cocktail) Therapy 1 Best Class NNI ¢ Potential best-in-class HCV NNI with a Bore Treatment strong profile Genotype (mg) Frequency ¢ Broad-spectrum, potent NS5B polymerase cc-31244 Gen
Slide 25: Favorable HCV Phase 2a Trial Results with CC-31244
Ake Lot Favorable HCV Phase 2a Trial Results with CC-31244 6 weeks of Epclusa® therapy including 2 weeks of CC-31244 Treatment was well tolerated with no study discontinuations due to adverse events 8 of 12 subjects (67%) achieved both SVR12 and SVR24, considered virologic cure 4 patients had virolo
Slide 26: Overview | Antiviral Program: Norovirus Gastroenteritis
26 Overview | Antiviral Program: Norovirus Gastroenteritis
Slide 27: Norovirus: No Approved Treatment
4 N Norovirus: No Approved Treatment Norovirus Polymerase and Protease Crystals eae Estimated annual cost of $60 billion worldwide due to healthcare costs and lost productivity’ ~685 Million 19-21 Million infections worldwide annually’ cases in the U.S.1 465,000 109,000 emergency department visits i
Slide 28: Potential for Developing First Norovirus Therapy
Ake Lot Potential for Developing First Norovirus Therapy ¢ Potent, broad-spectrum polymerase and protease inhibitors licensed from KSURF ¢ Structure-based lead molecule discovery ongoing Achieved Milestones and Next Steps: ¥ Q2 2020 Filed Additional Patent Application ¢ H1 2021 Complete Proof-of-Con
Slide 29: Positioned for Growth
29 Positioned for Growth
Slide 30: Expanding Intellectual Property Portfolio
Ake LT Expanding Intellectual Property Portfolio _F ° Influenza A/B HCV ° Influenza A/B inhibitor NS5B (NNI) * Pending applications in U.S. and Issued patents in U.S. worldwide f alee : Pending applications in U.S. and - worldwide * Coronavirus =e * Issued patents in U.S. and major countries Pending
Slide 31: ~$100 Million Market Cap Financial Snapshot
4 N ~$100 Million Market cap * Clean balance sheet * No preferred shares * No debt * Only 243,000 warrants *Yahoo Finance, 3-month daily volume Financial Snapshot 3.6 Million Average 3 month daily share volume’ 68.6 Million 70.6 Million Celulnteln SHEE Fully diluted shares outstanding * ~$800,000/mo
Slide 32: Investment Highlights
Investment Highlights Applying proprietary structure-based drug design technology to develop first- and best- in-class broad-spectrum antiviral drugs Large market opportunities for the treatment of acute and chronic viral diseases including seasonal and pandemic influenza, COVID-19, hepatitis C, and
Slide 33: Thank you!
NASDAQ: COCP cocrystalpharma.com C@CRYSTAL Thank you! PaaeA ReM Aw, INC.
Cocrystal Pharma — Investor Presentation (January 2021) on 6ix